Bafna Pharmaceuticals will open for subscription today with its public issue of 64,00,000 equity shares of Rs 10 each at a price of Rs 40 per equity share (including share premium of Rs 30 per equity share) for cash aggregating Rs 25.60 crores .
The issue will constitute 40.05% of the post issue paid-up capital of the company. The issue price is 4 times of the face value. The shares are proposed to be listed on the BSE.
Objects of the issue are as follows:
* Brand building in domestic markets Rs 10.44 crore.
* Part payment of loan from SBI Rs 4 crore.
* Brand building in international markets Rs 3.03 crore.
* Setting up R&D facilities Rs 3 crore.
* MHRA Accrediation Rs 1.08 crore.
* Public Issue expenses Rs 2.05 crore.
Cameo Corporate Services is the Registrar to the Issue.
Ashika Capital and Keynote Corporate Services are the Lead Managers to the Issue.
Tuesday, May 27, 2008
Bafna Pharmaceuticals IPO opens for subscription
Subscribe to:
Post Comments (Atom)
DISCLAIMER
DISCLAIMER: INVESTING AND TRADING IS VERY RISKY AND FINANCIAL LOSSES ARE OFTEN THE RESULT.
Investment success is far from a sure thing. This site is solely intended for educational purposes. I am not a registered investment advisor and it is not my intention to provide anyone with investment advice. I am not recommending that any reader of this blog buy, sell, short, or engage in any other investment strategy based upon the content set forth herein. I strongly urge all readers to perform their own due diligence before investing and or trading their funds. I will not be responsible for any readers financial losses.
0 comments:
Post a Comment